Patent & Trade Mark
Cameron Smith
Cameron Smith

Level 14, 90 Collins St
Melbourne VIC 3000 AUSTRALIA
Tel +61 3 8618 4128
Fax +61 3 8618 4199
Recent Publications
15 Sep 2017
FB Rice is pleased to be part of a seminar which explores different avenues of early stage technology funding, with Jenny Petering, FB Rice and Scale Angels, Lusia Guthrie, an Industry expert and co-founder of LBT Innovations, and Michael Ng, Investment Manager at Blue Sky Venture Capital.

29 Jul 2016
The Intellectual Property Office of Singapore (IPOS) recently set a higher bar for allowance of post-grant amendments. The change in practice follows decisions in Ship's Equipment Centre Bremen GmbH v Fuji Trading (Singapore) Pty Ltd & Ors [2015] SGHC 159 and more recently Warner-Lambert Company LLC v Novartis (Singapore) Pte Ltd [2016] SGHC 106 where the Singapore High Court affirmed the guidelines for allowance of post-grant amendments set down in the UK.

19 Oct 2015
The Australian Patent Office proposes to exclude nucleic acids coding for polypeptides from patentability and retain patent eligibility for most other naturally occurring products, such as antibodies, polypeptides and stems cells. The proposal from IP Australia has issued in light of the High Court of Australia’s ruling that an isolated nucleic acid, coding for a mutant BRCA1 protein, is not a "patentable invention".

Cameron is a registered Australian and New Zealand Patent Attorney with extensive experience in managing International patent portfolios in the Biotechnology space. Regular counsel is provided to clients in relation to strategic planning, due diligence and patentability advice with clients ranging from publicly listed biotechnology companies to smaller ‘start-up’ companies and university commercialisation teams. Counsel is primarily sought after in relation to diagnostics and biological therapeutics such as antibodies and stem cells.


Holding a bachelor of Biotechnology (honours), a PhD in molecular biology and a Masters in Commercial Law, Cameron is equally comfortable working directly with boards, leadership teams or in-house counsel, having demonstrated the motivation, interpersonal skills and knowledge required to work effectively across different levels and areas of an organisation. 


PhD research focused on a class of small RNA molecules known as microRNA’s.  Studies investigated the role of microRNA’s in an upper gastrointestinal disease sequence characterised by its systematic progression from gastroesophageal reflux disease (GORD) to Barrett’s oesophagus and oesophageal cancer.  Research projects focused on investigating microRNA mediated mechanisms for cancer development, in addition to characterising microRNAs as useful diagnostic and prognostic biomarkers.


Honours research investigated neuronal changes that occur during chronic heart failure development and how these changes might be targeted to slow or arrest the progression of this disease.  During his honours year, Cameron also won the Nick McClure Prize in Enterprise Management, graduating top of his class in a course designed to develop the skills required for the commercialisation of technology via a ‘start-up’ biotechnology company.


Cameron is also actively involved in intellectual property education, providing regular talks to assist organisations with raising awareness of intellectual property and developing intellectual property strategy.


  • Master of Commercial Law, The University of Melbourne
  • PhD in Biochemistry and Molecular Biology, Flinders University of South Australia
  • Bachelor of Biotechnology (Honours) specialising in Medical and Pharmaceutical Biotechnology

Areas of Interest

  • Pharmaceutical and Agricultural Biotechnology
  • Molecular and Cellular Biology
  • Tumour Biology
  • Genetics
  • Biochemistry
  • Gastrointestinal Pathologies
  • In vivo Models
  • Biomarkers
  • Small RNA Molecules
  • microRNAs
  • Small molecule biochemistry
  • Commercialisation

Industry Focus

Professional Affiliations

  • Member of the Institute of Patent and Trade Mark Attorneys of Australia
  • Member of the Intellectual Property Society of Australia and New Zealand
  • Member of the Progression of Barrett's Oesophagus to Cancer Network (PROBE-NET)
  • Member of the Flinders Centre for Cancer Prevention and Control
  • Member of the Flinders Centre for Neuroscience